Aktienanalyse zu BridgeBio Pharma, Inc. (BBIO)BBIOBridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

BridgeBio Pharma Inc is currently a hold rather than a buy due to its low RSI of 18.981, indicating it is oversold, and a significant 53.20% increase over the past year, suggesting strong historical performance. However, the recent 6.01% decline over the last five days and ongoing net losses, with a net income of -152216000 USD in Q2 2026, raise concerns about short-term stability. The main risk is the company's negative net margin of -63.97% in Q2 2026, which indicates ongoing financial struggles despite positive revenue growth.